Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Antianginal Drugs: Nitrates and β-Blockers

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Differential expression of cancer-related genes supports prediction of poor response to first-line treatments in T-ALL pediatric patients with high minimal residual disease.

Molecular oncology·2026

Same author

Revealing the Complexity of Allergies in Spain: A Multicenter Study on Sensitization Patterns and Clinical Implications.

Journal of investigational allergology & clinical immunology·2026

Same author

Bioaccessibility of phloretin and its derivatives using a dynamic in vitro digester. Effects on glucose uptake, bacterial growth and anti-inflammatory activity.

Food research international (Ottawa, Ont.)·2026

Same author

Posttranscriptional control of the B cell receptor by HuR is essential for innate B cell maintenance and function.

Proceedings of the National Academy of Sciences of the United States of America·2025

Same author

Improved identification of T-ALL paediatric patients with low MRD but poor prognosis using a transcriptional signature.

British journal of haematology·2025

Same author

Transcriptome-Wide Characterization of Protein:RNA Interactions with UV-Crosslinking Immunoprecipitation and Sequencing.

Methods in molecular biology (Clifton, N.J.)·2025

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

Prostaglandin Extraction and Analysis in Caenorhabditis elegans

Prostaglandin Extraction and Analysis in Caenorhabditis elegans

Published on: June 25, 2013

Prostanoid function and cardiovascular disease.

Miguel A Iñiguez¹, Cristina Cacheiro-Llaguno, Natalia Cuesta

¹Centro de Biología Molecular Severo Ochoa, Departamento de Biología Molecular, Universidad Autónoma de Madrid, Consejo Superior de Investigaciones Científicas, Cantoblanco, Madrid, Spain.

Archives of Physiology and Biochemistry

|July 17, 2008

Summary

Prostanoids regulate cardiovascular homeostasis and disease. Further research is needed to understand the benefits and risks of cyclooxygenase (COX) inhibitors in cardiovascular diseases.

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Related Experiment Videos

Last Updated: Jul 3, 2026

Prostaglandin Extraction and Analysis in Caenorhabditis elegans

Prostaglandin Extraction and Analysis in Caenorhabditis elegans

Published on: June 25, 2013

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Area of Science:

Biochemistry
Cardiovascular Physiology
Pharmacology

Background:

Prostanoids, including prostaglandins (PGs) and thromboxanes (TXs), are synthesized from arachidonic acid via cyclooxygenases (COXs) and specific synthases.
These signaling molecules are released extracellularly, acting on prostanoid receptors to influence cellular functions.
Prostanoids play critical roles in cardiovascular homeostasis and the pathogenesis of vascular diseases like thrombosis and atherosclerosis.

Purpose of the Study:

To review the roles of prostanoids, particularly Thromboxane A2 (TXA2) and Prostacyclin (PGI2), in vascular homeostasis.
To highlight the importance of prostanoid-mediated actions in cardiovascular physiology.
To emphasize the need for further investigation into prostanoid actions in the vascular system to clarify the benefits and risks of COX inhibitors in cardiovascular diseases.

Main Methods:

Review of existing literature on prostanoid synthesis and function.
Analysis of studies utilizing pharmacological COX inhibitors and genetically modified mouse models.
Examination of the roles of TXA2 and PGI2 in platelet activation, vasoconstriction, and vasodilation.

Main Results:

TXA2 is a potent activator of platelets and a vasoconstrictor.
PGI2 acts as a platelet inhibitor and vasodilator.
Prostanoid actions are crucial for maintaining vascular homeostasis.
COX inhibitors and genetic deficiencies have illuminated prostanoid-dependent cardiovascular functions.

Conclusions:

Prostanoids are key regulators of vascular homeostasis and disease.
Understanding the balance between TXA2 and PGI2 is essential for cardiovascular health.
Further research is required to fully elucidate the therapeutic implications of modulating prostanoid pathways, especially concerning COX inhibitors in cardiovascular disease management.